Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- Activist Jana Partners calls for Six Flags sale - WSJ
- Oil holds near two-week lows while diesel cracks hit record
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
RBC Capital Cuts Price Target on Endo Int'l (ENDP) Following Guidance Update
September 29, 2015 7:42 AM EDTRBC Capital maintained a Top Pick rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $100.00 (from $107.00), following a guidance update. ENDP pointed to a 3Q range of $720-740 million in revenue which is 4% below consensus at the midpoint.
Analyst... More
ACETO Corp (ACET) Unit to Acquire Three ANDAs from Endo (ENDP)
September 28, 2015 8:04 AM EDTACETO Corp (NASDAQ: ACET) announced that Rising Pharmaceuticals, Inc., its generic finished dosage form subsidiary, has reached agreement to purchase three ANDAs from a subsidiary of Endo International plc (Nasdaq: ENDP) for the products Methimazole Tablets, Glycopyrrolate Tablets and... More
Endo Int'l (ENDP) Closes Par Pharma Acquisition; Updates Guidance
September 28, 2015 6:34 AM EDTEndo Int'l (NASDAQ: ENDP) announced it has completed its previously announced $8.05 billion acquisition of Par Pharmaceutical Holdings, Inc. from leading global private investment firm TPG.
Through this acquisition, Endo has further established its position as a leading global specialty pharmaceutical company with a fast growing generics business that is among the top five as measured by U.S. sales according to IMS. The acquisition also helps position Endo for long-term double-digit organic growth, enhanced cash flow generation and increased financial flexibility. Endo's generics portfolio now includes an extensive range of in market and... More
